



Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
Date | Price Target | Rating | Analyst |
---|---|---|---|
7/16/2025 | $24.00 | Buy | Lake Street |
4/5/2024 | $12.00 | Perform → Outperform | Oppenheimer |
9/25/2023 | $19.00 | Buy | H.C. Wainwright |
4/17/2023 | $14.00 → $13.00 | Strong Buy → Outperform | Raymond James |
10/15/2021 | $28.00 → $37.00 | Hold → Buy | Canaccord Genuity |
8/20/2021 | Perform | Oppenheimer | |
7/14/2021 | $24.00 → $28.00 | Hold | Canaccord Genuity |
7/9/2021 | $27.00 → $32.00 | Strong Buy | Raymond James |
Lake Street initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $24.00
Oppenheimer upgraded AngioDynamics from Perform to Outperform and set a new price target of $12.00
H.C. Wainwright initiated coverage of AngioDynamics with a rating of Buy and set a new price target of $19.00
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angi
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference at 9:00 a.m. ET on Tuesday, August 12, 2025. A live webcast of the fireside chat will be accessible through the "Investors" section of the Company's website at www.angiodynamics.com and will be available for replay following the event.
Trial Investigates Use of Auryon Atherectomy System in Cases with Challenging Below-the-Knee Blockages AngioDynamics, Inc. (NASDAQ:ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced enrollment of the first patient in the Randomized Study of the Auryon Atherectomy System Used in Combination with Standard Balloon Angioplasty Versus Standard Balloon Angioplasty Alone Treating Infrapopliteal Lesions in Subjects with Critical Limb Ischemia Below-the-Knee (AMBITION BTK). AMBITION BTK is a prospective, multicenter, randomized controlled trial (RCT) d
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
DEFA14A - ANGIODYNAMICS INC (0001275187) (Filer)
DEF 14A - ANGIODYNAMICS INC (0001275187) (Filer)
10-K - ANGIODYNAMICS INC (0001275187) (Filer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
4 - ANGIODYNAMICS INC (0001275187) (Issuer)
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burgess to the Company's Board of Directors. Ms. Burgess brings over 35 years of management, financial, and global operations experience, including over 15 years at Medtronic, Inc., where she was responsible for the company's Americas Region as CFO, Vice President of Finance. While at Medtronic, Ms. Burgess led optimization initiatives that drove operational efficiencies and significant cost reductions. "Ms
PAVmed Inc. (NASDAQ:PAVM, PAVMZ))) (the "Company" or "PAVmed"), a diversified commercial-stage medical technology company and parent of cancer prevention company Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid"), today announced the appointment of Shaun O'Neil to serve as Executive Vice President and Chief Operating Officer, overseeing diverse corporate operations and commercial activities across the Company and its subsidiaries. Mr. O'Neil has served as PAVmed's Chief Commercial Officer and Executive Vice President, Business Development since joining the Company in 2018. He will serve on the Company's Executive Committee and as an executive officer pursuant to Section 16(a) of the Securities
VALENCIA, Calif. and MELBOURNE, Australia, June 01, 2021 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ:RCEL, ASX: AVH))) ("AVITA Medical"), a regenerative medicine company that is developing and commercializing a technology platform that enables point-of-care autologous skin restoration for multiple unmet needs, announced today the appointment of James Corbett and Jan Stern Reed to its Board of Directors effective July 1, 2021. Mr. Corbett has approximately 40 years of leadership experience in the medical device field, most recently, as CEO of CathWorks Ltd., a software-based medical technology company. Mr. Corbett has extensive global commercial and operating experience, serving as an
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market open on Thursday, October 2, 2025. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angi
Med Tech franchise delivers third consecutive quarter of over 20% revenue growth Reported strong adjusted EBITDA in the fourth quarter resulting in positive adjusted EBITDA for full fiscal year 2025 Drove $16.2 million of free cash flow in the quarter as a result of strong topline growth and operational efficiency efforts AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2025, which ended May 31, 2025. Fiscal Year 2025 Fou
AngioDynamics, Inc. (NASDAQ:ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the fourth quarter and fiscal year 2025 before the market open on Tuesday, July 15, 2025. The Company's management will host a conference call at 8:00 am ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international). This conference call will also be webcast and can be accessed from the "Investors" section of the Angio
SC 13G - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)
SC 13G/A - ANGIODYNAMICS INC (0001275187) (Subject)